Karyopharm Therapeutics | KPTI - Net Income


Karyopharm Therapeutics reported $-102.2M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Abbott USD 1.08B 699M Mar/2026
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Eli Lilly USD 7.4B 760M Mar/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
GlaxoSmithKline GBP 1.74B 1.1B Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
J&J USD 5.24B 119M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Nektar Therapeutics USD -36.08M 978K Dec/2025
Novartis USD 3.16B 747M Mar/2026
Novartis USD 2.41B 1.52B Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Takeda JPY -24.32B 127.96B Mar/2026
Tectonic Therapeutic USD -19.23M 186K Dec/2025
TG Therapeutics USD 19.78M 3.26M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Xencor USD -128.92M 122.26M Mar/2026